Health Care · Biological Products, (No Diagnostic Substances)

AMGN Amgen SEC Filings & Insider Trading Activity 2026

company
CIK 318154126 filings
Nasdaq 100
S&P 500

AMGN at a glance

Amgen (AMGN, SEC CIK 318154) filed its latest 10-K annual report on February 13, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as November 9, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Amgen (AMGN) reported revenue of $36.8 billion (up 10.0% from FY2024) and net income of $7.7 billion. Diluted EPS was $14.23.
  • As of September 30, 2026, 63 institutional investment managers tracked by SignalX reported holding Amgen (AMGN) shares worth $89.8 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Khosla Rachna on August 13, 2026 of 1,252 shares at $416.43 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$36.8B
+10.0% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
63 funds
$89.8B · −1 vs prior quarter
Latest 8-K
Nov 3, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Biopharmaceutical company focused on innovative therapies for serious illnesses
  • NEW segment emphasis: Integration and conversion of Horizon Therapeutics' equity plans post-acquisition in October 2023
  • Strategic shift: Acquisition of Horizon Therapeutics with stock plans merged, ending Horizon plans for future grants as of Oct 6, 2023
  • Quantitative metric: 11,230,989 total securities issuable under Amgen and acquired equity plans, weighted-average exercise price $234.45
  • Noteworthy fact: Performance units granted in 2023-2025 can yield up to 200% of target shares based on performance goals

Management Discussion & Analysis

  • Cash and equivalents $9.1B in 2025 vs $12.0B in 2024, decline of $2.9B
  • Long-term debt decreased to $50.0B in 2025 from $56.5B in 2024
  • Dividends per share increased 6% YoY to $2.38 in 2025 from $2.25 in 2024
  • No stock repurchases in 2025, $200M repurchased in 2024, $6.8B repurchase authorization remains
  • Management confident in liquidity from operations, debt markets, and existing cash for capital needs and shareholder returns

Risk Factors

  • Litigation risk: Ongoing U.S. Antitrust trial with Regeneron; jury awarded $135.6M compensatory damages, potential trebling to $406.8M total damages
  • Geopolitical exposure: Patent disputes in Germany and Japan with Sanofi and Regeneron, including upheld EP’004 patent validity and ongoing appeals
  • Supply chain/operational vulnerability: Multi-jurisdictional patent litigation delays marketing; UPC actions and EPO oppositions prolong product launches like Repatha and PAVBLU
  • Competitive risk: Multiple biosimilar patent infringement lawsuits filed against five companies including Amneal, Hikma, Dr. Reddy’s, Alkem seeking to enter U.S. market for Prolia/XGEVA
  • Financial risk: $1.8B final U.S. repatriation tax payment made in 2025 under 2017 Tax Act, material cash outflow impacting liquidity planning

AI summary of the AMGN 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $10,365M, up 8% YoY from $9,557M, driven by product-sales volume growth
  • Operating margin 35.8% vs 26.4% YoY, with operating income $3,710M vs $2,526M
  • Best product: Repatha $1,085M, worst: Prolia $1,139M, down 45% YoY amid biosimilar competition
  • Cash $13,190M vs $9,129M at December 31, 2025, with nine-month operating cash flow $10,432M vs $8,355M
  • Outlook: volume growth offset by net-price declines, with continued Prolia and XGEVA erosion from biosimilars

Risk Factors

  • TAVNEOS withdrawal risk: FDA proposed revoking U.S. approval after liver-injury concerns and questioned ADVOCATE data reliability
  • TAVNEOS international risk: European Commission revoked authorization in August 2026, with other regulators restricting or reviewing use
  • Medicare pricing pressure: CMS pricing reduced ENBREL profitability from January 1, 2026, with Otezla pricing beginning January 2027
  • State reimbursement risk: Colorado established an ENBREL upper payment limit effective no earlier than January 1, 2027
  • Regulatory capacity risk: FDA staffing and budget reductions could delay application reviews and approvals

AI summary of the AMGN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 3, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 and nine-month 2026 unaudited results, plus September 30 financial position, announced November 3, 2026
  • Exhibit 99.1 contains the earnings release with GAAP results and non-GAAP reconciliations

Item EX-99.1: Item EX-99.1

  • Q3 revenue $10.4B, up 8%, with product sales up 8% on volume growth and 17 products posting double-digit growth
  • GAAP EPS $7.08, up 19%, while operating margin expanded 9.9 points to 37.5%
Filed Oct 27, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • David W. Gibbs appointed director effective October 26, 2026, expanding the Board to 13 directors
  • Board remains highly independent: 12 of 13 directors independent

Item EX-99.1: Item EX-99.1

  • David W. Gibbs appointed immediately to Amgen’s Board, expanding oversight and consumer-brand expertise
  • Gibbs joins Audit Committee and Compensation and Management Development Committee
Filed Aug 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 and six-month 2026 unaudited results, plus June 30 financial position, announced August 4, 2026
  • Investors must review Exhibit 99.1 for revenue, earnings, cash flow and balance-sheet figures

Item EX-99.1: Item EX-99.1

  • Q2 revenue $10.1B, up 10%, with product sales up 9% and six growth drivers up 26%, supporting continued portfolio momentum
  • GAAP EPS $4.37, up 65%, while non-GAAP EPS $6.29, up 4%, reflecting higher expenses and tax pressure

AI summaries of AMGN 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for AMGN

Don't miss the next AMGN filing

  • Alerts as it files. A push when AMGN files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut AMGN, by share count.
  • Ask anything. An AI agent that reads every AMGN filing and answers with sources.

AMGN alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Drake Michael VANov 6, 2026-
ISHRAK OMARANov 6, 2026-
HOLLEY CHARLES MANov 6, 2026-
Gibbs David WANov 6, 2026-
Khosla RachnaSellAug 13, 2026$416.43
Khosla RachnaMAug 13, 2026-
Khosla RachnaMAug 13, 2026$162.60
Khosla RachnaSellAug 11, 2026$412.57

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$33.4B$36.8B
Operating Income-$7.3B$9.1B
Net Income$6.7B$4.1B$7.7B
Op. Margin-21.7%24.7%
Net Margin-12.2%21.0%
Balance Sheet
Total Assets$97.2B$91.8B$90.6B
Equity-$5.9B$8.7B
ROE-69.6%89.1%
Per Share
EPS$12.49$7.56$14.23
Cash Flow
Operating CF-$11.5B$10.0B
CapEx$1.1B$1.1B$1.9B

Source: XBRL data in Amgen (AMGN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate AMGN share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
AMGN shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202663$89.83B
Q2 202664$77.82B
Q1 202664$75.02B
Q4 202562$70.93B
Q3 202565$59.06B
Q2 202566$57.96B
Q1 202563$49.58B
Q4 202461$34.01B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 508 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

AMGN filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 9, 2026--
4Nov 9, 2026--
4Nov 9, 2026--
4Nov 9, 2026--
10-QNov 4, 2026Analysis
8-KNov 3, 2026Analysis-
8-KOct 27, 2026Analysis-
4Aug 13, 2026--
4Aug 12, 2026--
4Aug 10, 2026--
4Aug 10, 2026--
4Aug 10, 2026--
4Aug 7, 2026--
4Aug 7, 2026--
10-QAug 5, 2026Analysis
8-KAug 4, 2026Analysis-
8-KJul 31, 2026Analysis-
8-KMay 20, 2026Analysis
8-KMay 19, 2026Analysis
SC 13GMay 14, 2026-
4May 11, 2026-
4May 11, 2026-
4May 11, 2026-
4May 11, 2026-
4May 11, 2026-

Related Health Care companies

All Health Care →

AMGN SEC filings: frequently asked questions

Which institutions hold AMGN stock?

As of September 30, 2026, the largest Amgen (AMGN) holders among the 13F filers tracked by SignalX were BlackRock ($20.6 billion), Vanguard Capital Management LLC ($14.9 billion), State Street Corp ($13.0 billion), Invesco Ltd ($7.0 billion), Vanguard Portfolio Management LLC ($6.3 billion). 13F-HR reports are filed up to 45 days after each quarter ends.

What was AMGN's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Amgen (AMGN) reported revenue of $36.8 billion (up 10.0% from FY2024) and net income of $7.7 billion. Diluted EPS was $14.23. The figures come from the XBRL data in the 10-K.

What are the main risks in AMGN's latest 10-K?

In the 10-K filed February 13, 2026, Amgen (AMGN) flagged: Litigation risk: Ongoing U.S. Antitrust trial with Regeneron; jury awarded $135.6M compensatory damages, potential trebling to $406.8M total damages. Geopolitical exposure: Patent disputes in Germany and Japan with Sanofi and Regeneron, including upheld EP’004 patent validity and ongoing appeals. (AI summary of the Risk Factors section.)

What did AMGN report in its latest 8-K?

Amgen (AMGN) filed an 8-K on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 and nine-month 2026 unaudited results, plus September 30 financial position, announced November 3, 2026.

What are the latest AMGN SEC filings?

Amgen (AMGN) filed its latest 10-K annual report on February 13, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on November 9, 2026.

What is AMGN's SEC CIK number?

Amgen (AMGN)'s SEC Central Index Key (CIK) is 318154. EDGAR lists every AMGN filing under that number.

Ask anything about AMGN

The research agent reads AMGN's filings, financials, insider trades and 13F holders, then answers with sources.